News

FDA approves combination immunotherapy treatment for metastatic kidney cancer

FDA approves combination immunotherapy treatment for metastatic kidney cancer

 

The Food and Drug Administration grants approval for the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. The approval comes following the findings of the CheckMate-214 study, which was sponsored by Bristol-Myers Squibb and co-led by Dr. Hans Hammers. Press Release

Dr. Hannan and colleagues report on efficacy of immune checkpoint inhibition combined with SBRT

Dr. Hannan and colleagues report on efficacy of immune checkpoint inhibition combined with SBRT

 

Dr. Raquibul Hannan and colleagues report results from one of the largest series of cancer patients (mostly kidney and melanoma) treated with immune checkpoint inhibitors together with modern hypofractionated radiation, such as stereotactic body radiation therapy (SBRT). Abstract

Former kidney donor joins KCP staff as first Director of Patient Experience at UT Southwestern

Former kidney donor joins KCP staff as first Director of Patient Experience at UT Southwestern

 

The KCP welcomes Megan Dougherty, R.N., as Director of Patient Experience. Ms. Dougherty will be the first Director of Patient Experience at UT Southwestern.

KCP holds the 2nd Annual Rock the Cure event

KCP holds the 2nd Annual Rock the Cure event

 

KCP Community gathers at the Dallas Country Club for a fun fundraising event organized by patient advocate Merlinda Chelette.

Dr. Brugarolas speaks at the UTSW President's Advisory Board meeting

Dr. Brugarolas speaks at the UTSW President's Advisory Board meeting

 

Along with Dr. Arteaga (Director of Simmons Comprehensive Cancer Center) and Dr. Choy (Chairman of Radiation Oncology), Dr. Brugarolas addresses the President's Advisory Board at their yearly meeting on the healthcare mission of the academic medical center.

Seven minute whole-body MRI with improved detection of metastases

Seven minute whole-body MRI with improved detection of metastases

 

UT Southwestern investigators develop 7-minute whole body MRI protocol that allows improved detection of bone metastases in the whole body. Press Release  Video

Dr. Brugarolas awarded two CPRIT grants

Dr. Brugarolas awarded two CPRIT grants

 

Dr. Brugarolas receives two Individual Investigator Research Award grants from CPRIT totaling over $2 million - a renewal grant investigating the implications of BAP1 and PBRM1 loss in renal cancer, and a second grant, which focuses on a rare, but devastating form of renal cancer, translocation RCC. Press Release

State-of-the-art MRI technology bypasses need for biopsy

State-of-the-art MRI technology bypasses need for biopsy

 

Featured on the cover of the Journal of Urology, Drs. Pedrosa, Cadeddu, and colleagues report a new multiparametric MRI approach with high sensitivity and specificity for the detection of clear cell renal cell carcinoma, which may reduce the need for biopsiesPress Release  Video

HIF-2 inhibitor effective against kidney cancer

HIF-2 inhibitor effective against kidney cancer

 

The results of a Phase I clinical trial using a first-in-class HIF-2alpha inhibitor called PT2385 are reported in the Journal of Clinical Oncology. The drug, developed by Peloton Therapeutics, showed activity in highly pretreated patients and minimal side-effects. KCP researcher, Dr. Kevin Courtney, was the UTSW site PI and corresponding author of the report. Press Release 

KCP hosts first retreat for trainees

KCP hosts first retreat for trainees

 

The KCP hosted a retreat for trainees (medical students, interns, residents, fellows...) to discuss trainee projects, research opportunities, resources, and funding opportunities. Two $1,000 awards for best research projects were given - one to a student, Daniel Li (MS2), and one to a physician, Ali Pirasteh, M.D. (Assistant Instructor).